Olema Pharmaceuticals’ Preclinical Findings on OP-3136: A Novel Small Molecule Inhibitor of Lysine Acetyltransferase 6 (KAT6)
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, recently announced that it will present a poster at the American Association for Cancer Research (AACR) Annual Meeting highlighting the preclinical anti-tumor activity of OP-3136, a novel small molecule that selectively inhibits lysine acetyltransferase 6 (KAT6).
About OP-3136 and KAT6
OP-3136 is a small molecule that has been shown to potently inhibit KAT6, an enzyme involved in the regulation of gene expression through the acetylation of histones and non-histone proteins. The overexpression of KAT6 is linked to various cancers, including prostate, ovarian, and non-small cell lung cancer.
Preclinical Findings
In the preclinical studies, OP-3136 demonstrated significant anti-tumor activity in prostate, ovarian, and non-small cell lung cancer models. Specifically, in prostate cancer models, OP-3136 inhibited the growth of tumors by up to 80% compared to the control group. In ovarian cancer models, OP-3136 decreased tumor size by up to 70%. In non-small cell lung cancer models, OP-3136 reduced tumor growth by up to 60%.
Poster Presentation Details
The poster presentation, titled “OP-3136, a selective KAT6 inhibitor, demonstrates anti-tumor activity in prostate, ovarian, and non-small cell lung cancer preclinical models,” will be presented by Dr. Gopinath S. in the Late-Breaking Research: Tumor Biology 2 session on April 28, 2025. The session will take place from 9:00am-12:00pm Central Time (CT) or 10:00am-1:00pm Eastern Time (ET).
Implications for Patients and the World
These findings suggest that OP-3136 could be a promising therapeutic agent for the treatment of various cancers where KAT6 overexpression has been observed. For patients, this could mean a new treatment option for those diagnosed with prostate, ovarian, or non-small cell lung cancer. Furthermore, the development of OP-3136 could also have a significant impact on the global cancer treatment landscape, as it represents a novel approach to targeting KAT6 and its role in cancer growth and progression.
Conclusion
Olema Pharmaceuticals’ preclinical findings on OP-3136, a novel small molecule inhibitor of KAT6, demonstrate its potential as a therapeutic agent for various cancers where KAT6 overexpression has been observed. The upcoming poster presentation at the AACR Annual Meeting will provide further insights into the anti-tumor activity of OP-3136 in prostate, ovarian, and non-small cell lung cancer models. These findings could ultimately lead to a new treatment option for patients diagnosed with these cancers and have a significant impact on the global cancer treatment landscape.
- Olema Pharmaceuticals to present preclinical findings on OP-3136, a novel small molecule inhibitor of KAT6, at AACR Annual Meeting
- OP-3136 demonstrated significant anti-tumor activity in prostate, ovarian, and non-small cell lung cancer models
- Poster presentation details: Title, Session, Date/Time, Presenter
- Findings could lead to a new treatment option for patients with various cancers and impact the global cancer treatment landscape
